Aligos Therapeutics, Inc. (ALGS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-21

Key Insights

Aligos secured a $25 million upfront payment from Amoytop for exclusive rights to develop and commercialize pevifoscorvir sodium in Greater China (mainland China, Taiwan, Hong Kong, Macau) for Hepatitis B/D treatment, providing near-term cash and validating the asset's commercial potential in a major market.
The deal structure includes up to $420 million in future development, regulatory, and commercial milestones plus high single-digit tiered royalties, offering significant upside if Amoytop successfully advances the compound through development and commercialization in the territory.
Aligos retains key rights to manufacture and develop the Licensed Product outside the Territory and Field, maintains access to Amoytop's manufacturing improvements on a non-exclusive basis, and has a 7-year right of first negotiation for novel formulations, preserving strategic flexibility and global optionality.

Want the newest filings?

This analysis covers the filing from 2026-04-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-14

Aligos Therapeutics announced positive interim results from the Phase 2 B-SUPREME study of its HBV drug candidate pevifoscorvir sodium, with the independent data safety monitoring board recommending continuation of the study with an increased sample size.
The company received Fast Track Designation from the FDA for pevifoscorvir sodium, indicating the drug's potential as a best-in-class or first-in-class treatment for chronic HBV infection.
The positive clinical data and regulatory milestone for pevifoscorvir suggest continued progress in Aligos's pipeline and could signal future value creation for shareholders.

Other reports for Aligos Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.